Good Clinical Practices (GCP) have always been critical to ethical scientific and medical research in humans, especially when it comes to developing new therapies that have to go through the mandatory clinical trial phase. Since their foundation, the ICH GCP guidelines have been a key element in upholding these ethics and promoting participant safety and regulatory compliance in the life sciences industry.
Now, with the adoption of the latest revision of the ICH E6 (R3) Guideline for good clinical practice (GCP), which will come into effect on 23 July, 2025, we are moving closer toward a more flexible, modern, and proportionate approach to clinical trial conduct that reflects today’s complex and dynamic scientific and medical landscape within the broader life sciences industry.